1. Home
  2. TNET vs AKRO Comparison

TNET vs AKRO Comparison

Compare TNET & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNET
  • AKRO
  • Stock Information
  • Founded
  • TNET 1988
  • AKRO 2017
  • Country
  • TNET United States
  • AKRO United States
  • Employees
  • TNET N/A
  • AKRO N/A
  • Industry
  • TNET Business Services
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TNET Consumer Discretionary
  • AKRO Health Care
  • Exchange
  • TNET Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • TNET 3.9B
  • AKRO 3.9B
  • IPO Year
  • TNET 2014
  • AKRO 2019
  • Fundamental
  • Price
  • TNET $70.37
  • AKRO $45.15
  • Analyst Decision
  • TNET Hold
  • AKRO Strong Buy
  • Analyst Count
  • TNET 3
  • AKRO 8
  • Target Price
  • TNET $89.50
  • AKRO $80.38
  • AVG Volume (30 Days)
  • TNET 436.4K
  • AKRO 856.3K
  • Earning Date
  • TNET 10-24-2025
  • AKRO 08-08-2025
  • Dividend Yield
  • TNET 1.54%
  • AKRO N/A
  • EPS Growth
  • TNET N/A
  • AKRO N/A
  • EPS
  • TNET 2.85
  • AKRO N/A
  • Revenue
  • TNET $4,993,000,000.00
  • AKRO N/A
  • Revenue This Year
  • TNET $2.47
  • AKRO N/A
  • Revenue Next Year
  • TNET $3.23
  • AKRO N/A
  • P/E Ratio
  • TNET $25.01
  • AKRO N/A
  • Revenue Growth
  • TNET 0.73
  • AKRO N/A
  • 52 Week Low
  • TNET $62.55
  • AKRO $21.34
  • 52 Week High
  • TNET $100.05
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • TNET 55.91
  • AKRO 39.03
  • Support Level
  • TNET $70.15
  • AKRO $43.08
  • Resistance Level
  • TNET $72.84
  • AKRO $46.18
  • Average True Range (ATR)
  • TNET 1.86
  • AKRO 1.62
  • MACD
  • TNET 0.53
  • AKRO -0.29
  • Stochastic Oscillator
  • TNET 67.04
  • AKRO 32.18

About TNET TriNet Group Inc.

TriNet offers outsourced payroll and human capital management solutions for small and midsize businesses via a professional employer organization model. Under the PEO model, TriNet enters a co-employment arrangement and acts as the employer of record for administrative and regulatory purposes for clients' employees, known as worksite employees. Clients leverage the scale and expertise of TriNet to access competitive employee benefits, share employment risk liability, access compliance support, and outsource mission-critical day-to-day HR functions such as payroll and tax administration. Following the acquisition of Zenefits and Clarus R+D in 2022, TriNet derives the minority of its revenue from self-service HCM software and R&D tax credit services.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: